Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jul 1;35(8):1191-1199.
doi: 10.1097/QAD.0000000000002857.

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV

Jeremiah D Momper  1 , Jiajia Wang  2 , Alice Stek  3 , David E Shapiro  2 , Gwendolyn B Scott  4 , Mary E Paul  5 , Irma L Febo  6 , Sandra Burchett  7 , Elizabeth Smith  8 , Nahida Chakhtoura  9 , Kayla Denson  10 , Kittipong Rungruengthanakit  11 , Kathleen George  12 , Derek Z Yang  1 , Edmund V Capparelli  1 , Mark Mirochnick  13 , Brookie M Best  1 ; IMPAACT P1026s Protocol Team
Affiliations
Clinical Trial

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV

Jeremiah D Momper et al. AIDS. .

Abstract

Objective: To evaluate darunavir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.

Design: Nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of darunavir and cobicistat pharmacokinetics in pregnant women with HIV and their children in the United States.

Methods: Intensive steady-state 24-h pharmacokinetic profiles were performed after administration of 800 mg of darunavir and 150 mg of cobicistat orally in fixed dose combination once-daily during the second trimester, third trimester, and postpartum. Infant washout samples were collected after birth. Darunavir and cobicistat were measured in plasma by validated HPLC-UV and liquid chromatography with tandem mass spectrometry detection (LC-MS)/MS assays, respectively. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-participant comparisons.

Results: A total of 29 pregnant women receiving darunavir and cobicistat once-daily enrolled in the study. Compared with paired postpartum data, darunavir AUC0--24 was 53% lower in the second trimester [n = 12, P = 0.0024, geometric mean of ratio (GMR)=0.47, 90% confidence interval (CI) 0.33 - 0.68] and 56% lower in the third trimester (n = 18, P < 0.0001, GMR = 0.44, 90% CI 0.36 - 0.54), whereas cobicistat AUC0--24 was 50% lower in the second trimester (n = 12, P = 0.0024, GMR = 0.50, 90% CI 0.36-0.69) and 56% lower in the third trimester (n = 18, P < 0.0001, GMR = 0.44, 90% CI 0.35-0.55). Placental transfer of darunavir and cobicistat was limited.

Conclusion: Standard darunavir/cobicistat dosing during pregnancy results in significantly lower exposure during pregnancy, which may increase the risk of virologic failure and perinatal transmission.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Median antepartum and postpartum plasma darunavir (a) and cobicistat (b) concentration versus time profiles at steady state following once-daily dosing of 800/150 mg darunavir/cobicistat. The shaded area displays the 10th to 90th percentile concentrations of darunavir in non-pregnant adults.
Figure 2.
Figure 2.
Scatter plot of darunavir plasma concentrations in cord blood and in infants after birth. Concentrations below the limit of quantitation (BLQ; 0.09 μg/mL) are displayed as 1/2 the lower limit of quantitation (0.045 μg/mL). Darunavir was BLQ in 15 of 19 available cord blood samples. A total of 85 washout samples were obtained from 26 infants over the first 9 days of life. In 17 infants all samples were BLQ for darunavir.
See this image and copyright information in PMC

References

    1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission [September 30, 2019]; Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
    1. Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol 2014; 5:65. - PMC - PubMed
    1. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol 2015; 39(7):512–519. - PMC - PubMed
    1. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43(15):1071–1087. - PubMed
    1. Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, et al. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. J Acquir Immune Defic Syndr 2015; 70(1):33–41. - PMC - PubMed

Publication types